Shield Therapeutics Raises EUR8.2 Million From Inventages Venture Capital via Series A Institutional Round

By Shield Therapeutics, PRNE
Tuesday, May 31, 2011

LONDON, June 1, 2011 -

- New Investment to Further Fund the Phase III Clinical Programme of
ST10-021 in Iron Deficiency Anaemia

Shield Therapeutics (Shield), the independent specialty
pharmaceutical company focused on the development and commercialisation of
late-stage hospital pharmaceuticals, today announces that it has successfully
raised EUR8.2m (CHF10m/US$12m) from Inventages Venture Capital (Inventages)
in its first institutional (Series A) financing round.

"We are delighted to have successfully completed this
fundraising which serves as further validation of the potential of ST10-021
as a novel treatment for iron deficiency anaemia and Shield's development
strategy," said Carl Sterritt, Chief Executive Officer and Co-Founder of
Shield Therapeutics. "We look forward to working closely with the Inventages
team to benefit from both their experience of working with high-growth
companies like Shield and their excellent track record in helping to create
significant value for shareholders. Shield is now well positioned to build
upon the progress achieved to date as we can accelerate our plans and
commence AEGIS I and II - the pivotal trials for ST10-021 - during 2011."

The new investment will help fund the Phase III pivotal
development programme and subsequent filing of a marketing authorisation
application for ST10-021, a novel stable complex of ferric iron in an oral
formulation initially being developed for the treatment of iron deficiency
anaemia, a key symptom of both ulcerative colitis and Crohn's disease. Shield
Therapeutics will commence international Phase III trials of ST10-021 in
patients with these indications in the second half of 2011.

The investment by Inventages follows the recent completion of
a final private investor led fundraising and was made at a post-money
valuation of EUR35m (CHF43m/US$51m). The investment is scheduled in two equal
tranches over the next two years. Prior to the investment by Inventages,
Shield Therapeutics successfully completed three private investment rounds,
raising a total of approximately EUR6 million (CHF7.5m/US$9.0m).

Gunnar Weikert, the Chairman of Inventages who will be joining
the Board of Shield Therapeutics, commented: "We are excited by the
opportunity to work together with the dynamic and experienced team of Shield
and to develop this novel treatment for iron deficiency anaemia, which is one
of the most common global disorders. ST10-021 has the potential to help a
large number of patients who are currently on intravenous therapy or cannot
cope with the side effects of oral ferrous drugs."

Shield Therapeutics was advised on the transaction by law
firms Turner Parkinson (in the UK) and Kellerhals (in Switzerland).

About Shield Therapeutics

Shield Therapeutics, founded in 2008, is an independent
specialty pharmaceutical company focused on the development and
commercialisation of late-stage, mineral-derived hospital pharmaceuticals
which address areas of high unmet medical need. During 2011 Shield will be
commencing global pivotal Phase III studies of its lead asset, ST10-021, for
the treatment of iron deficiency anaemia associated with inflammatory bowel
disease and subsequently chronic kidney disease. The Company is headquartered
in Wollerau, Switzerland. For further information, please visit

About Inventages Venture Capital

Inventages is one of the world's biggest specialised life
science venture capital investors with US$1.5 billion committed capital. It
invests globally in healthcare, medical nutrition and consumer health and
operates out of four offices: Nassau (Bahamas), London (United Kingdom),
Geneva (Switzerland), and Auckland (New Zealand). Beyond capital infusion and
board participation, Inventages strives to contribute to the growth of the
management teams and companies in which they invest by leveraging its
experience, together with extensive networks and relationships. For further
information, please visit

For more information about Shield, please contact:

    Mary-Jane Elliott / Emma Thompson
    Tel +44(0)20-7920-2342


will not be displayed